Thrombolex, Inc. Secures $50 Million Series A Growth Financing to Advance Commercialization of its Innovative Pharmaco-Mechanical Lysis Technology (PML). Thrombolex, a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed, with strong support from current investors and co-founders.

New Britain, PA March 16, 2026 --(PR.com)-- Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a $50 million Series A equity financing led by OrbiMed, with strong support from current investors and co-founders.

The financing strengthens the Company’s capital position as it expands U.S. commercial infrastructure and advances clinical evidence generation across its endovascular catheter platform.

Thrombolex’s FDA cleared BASHIR™ Endovascular Catheter (BEC) systems are designed to enable rapid thrombus reduction using a single-session, on-the-table, ...